Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms

Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries

Fast track promising assets from discovery to clinical proof of concept

Advance programs into pivotal studies and commercialization through creative partnerships

Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise